Last reviewed · How we verify
PD-1 and PD-L1 inhibitor
PD-1 and PD-L1 inhibitor is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently in Phase 1 development.
At a glance
| Generic name | PD-1 and PD-L1 inhibitor |
|---|---|
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Hypertension
- Decreased appetite
- Fatigue
- Nausea
- Hypothyroidism
- Weight decreased
- Constipation
- Aspartate aminotransferase increased
- Vomiting
- Alanine aminotransferase increased
- Palmar-plantar erythrodysaesthesia syndrome
Key clinical trials
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 and PD-L1 inhibitor CI brief — competitive landscape report
- PD-1 and PD-L1 inhibitor updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI
Frequently asked questions about PD-1 and PD-L1 inhibitor
What is PD-1 and PD-L1 inhibitor?
PD-1 and PD-L1 inhibitor is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital.
Who makes PD-1 and PD-L1 inhibitor?
PD-1 and PD-L1 inhibitor is developed by Tianjin Medical University Cancer Institute and Hospital (see full Tianjin Medical University Cancer Institute and Hospital pipeline at /company/tianjin-medical-university-cancer-institute-and-hospital).
What development phase is PD-1 and PD-L1 inhibitor in?
PD-1 and PD-L1 inhibitor is in Phase 1.
What are the side effects of PD-1 and PD-L1 inhibitor?
Common side effects of PD-1 and PD-L1 inhibitor include Diarrhoea, Hypertension, Decreased appetite, Fatigue, Nausea, Hypothyroidism.